Discuss the potential benefits of phentolamine mesylate (OraVerse) for post-anesthetic care for children
What will be an ideal response?
OraVerse (phentolamine mesylate), an injectable formulation by Novalar Pharmaceuticals, is the first pharmaceutical agent available for the reversal of soft-tissue anesthesia which often interfere with speaking, eating, and drinking. Additionally, there is early evidence that OraVerse may reduce the risks of postoperative soft tissue injury occurring during and after local anesthesia, especially in children.
Objective 7
True or false
You might also like to view...
Accumulation of fluid as a result of systemic disease is defined as:
a. Exudate b. Chylous fluid c. Transudate d. Peritoneal ascites
Which of the following is(are) the clinical application(s) of flow cytometry?
a. Assessment of total body iron b. Immunophenotyping c. DNA amplification d. Cytogenetic analysis